121 related articles for article (PubMed ID: 31818713)
21. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
[TBL] [Abstract][Full Text] [Related]
22. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation.
Hoskins PJ; Le N; Gilks B; Tinker A; Santos J; Wong F; Swenerton KD
J Clin Oncol; 2012 May; 30(14):1656-62. PubMed ID: 22493415
[TBL] [Abstract][Full Text] [Related]
23. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
Matsuo K; Hasegawa K; Yoshino K; Murakami R; Hisamatsu T; Stone RL; Previs RA; Hansen JM; Ikeda Y; Miyara A; Hiramatsu K; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Roman LD; Gabra H; Fotopoulou C; Sood AK
Eur J Cancer; 2015 Sep; 51(14):1978-88. PubMed ID: 26238017
[TBL] [Abstract][Full Text] [Related]
24. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
26. Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study.
Schnack TH; Høgdall E; Nedergaard L; Høgdall C
Int J Gynecol Cancer; 2016 Jan; 26(1):82-90. PubMed ID: 26569060
[TBL] [Abstract][Full Text] [Related]
27. Endometriosis-associated ovarian cancer is not a distinct clinical entity among young patients: A 12-year cohort study.
Cai Y; Yin J; Jin Y; Li Y; Wu M; Yang J; Huang H; Leng J; Pan L
Eur J Surg Oncol; 2020 May; 46(5):876-882. PubMed ID: 31837932
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
Kuku S; Williams M; McCormack M
Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
[TBL] [Abstract][Full Text] [Related]
29. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J; Ke G; Bi R; Wu X
J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of Serum CA19-9 and Perioperative CA-125 Levels in Ovarian Clear Cell Carcinoma.
Zhu J; Jiang L; Wen H; Bi R; Wu X; Ju X
Int J Gynecol Cancer; 2018 Jul; 28(6):1108-1116. PubMed ID: 29781825
[TBL] [Abstract][Full Text] [Related]
32. Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.
Fehm T; Banys M; Rack B; Janni W; Marth C; Blassl C; Hartkopf A; Trope C; Kimmig R; Krawczyk N; Wallwiener D; Wimberger P; Kasimir-Bauer S
Int J Gynecol Cancer; 2013 Jun; 23(5):839-45. PubMed ID: 23694981
[TBL] [Abstract][Full Text] [Related]
33. Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute.
Zhao T; Shao Y; Liu Y; Wang X; Guan L; Lu Y
J Ovarian Res; 2018 Jun; 11(1):53. PubMed ID: 29941051
[TBL] [Abstract][Full Text] [Related]
34. Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.
Xu MJ; Chu C; Rubin S; Lin LL
Am J Clin Oncol; 2017 Dec; 40(6):598-604. PubMed ID: 26237194
[TBL] [Abstract][Full Text] [Related]
35. Immune-Hot tumor features associated with recurrence in early-stage ovarian clear cell carcinoma.
Huang RY; Huang KJ; Chen KC; Hsiao SM; Tan TZ; Wu CJ; Hsu C; Chang WC; Pan CY; Sheu BC; Wei LH
Int J Cancer; 2023 May; 152(10):2174-2185. PubMed ID: 36629283
[TBL] [Abstract][Full Text] [Related]
36. Effect of Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma: A Two-Center Cohort Study and Meta-analysis.
Kim HS; Kim MA; Lee M; Suh DH; Kim K; No JH; Chung HH; Kim YB; Song YS
Ann Surg Oncol; 2015 Aug; 22(8):2738-45. PubMed ID: 25680339
[TBL] [Abstract][Full Text] [Related]
37. Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis.
Rauh-Hain JA; Davis M; Clemmer J; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
Gynecol Oncol; 2013 Nov; 131(2):404-9. PubMed ID: 24004647
[TBL] [Abstract][Full Text] [Related]
38. Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC): a pragmatic cohort study of women with classic immuno-phenotypic signature.
Stevens MJ; West S; Gard G; Renaud C; Nevell D; Roderick S; Le A
Radiat Oncol; 2021 Feb; 16(1):29. PubMed ID: 33549120
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.
Shaboodien R; Diamantis N; Blagden S; Gabra H; Agarwal R
Int J Gynecol Cancer; 2013 Mar; 23(3):481-7. PubMed ID: 23392404
[TBL] [Abstract][Full Text] [Related]
40. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.
Prendergast EN; Holzapfel M; Mueller JJ; Leitao MM; Gunderson CC; Moore KN; Erickson BK; Leath CA; Diaz Moore ES; Cohen JG; Walsh CS
Gynecol Oncol; 2017 Feb; 144(2):274-278. PubMed ID: 27979319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]